U.S. flag An official website of the United States government
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Diasol Inc. - 535734 - 03/15/2022
  1. Warning Letters


Diasol Inc. MARCS-CMS 535734 —

Delivery Method:
VIA Electronic Mail
Medical Devices

Recipient Name
Monica F. Abeles
Recipient Title
Diasol Inc.

310 S 43rd Ave.
Ste B
Phoenix, AZ 85009
United States

Issuing Office:
Los Angeles District Office

United States

Dear Ms. Abeles:

The Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our Warning Letter (WL #535734-17) dated September 25, 2017. Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Jessica Mu
Director, Compliance Branch
Office of Medical Device and Radiological Health Operations
Division 3

Back to Top